Cardiovascular Risks, Bleeding Risks, and Clinical Events From 3 Phase III Trials of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis

Advances in Therapy - United States
doi 10.1007/s12325-019-01052-y
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Idiopathic Pulmonary Fibrosis and Pirfenidone

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2010English

Efficacy of Pirfenidone in Patients With Advanced-Stage Idiopathic Pulmonary Fibrosis

Internal Medicine
Internal MedicineMedicine
2013English

Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis and More Advanced Lung Function Impairment

Respiratory Medicine
PulmonaryRespiratory Medicine
2019English

Effect of Perioperative Pirfenidone Treatment in Lung Cancer Patients With Idiopathic Pulmonary Fibrosis

Annals of Thoracic Surgery
Respiratory MedicinePulmonaryCardiovascular MedicineSurgeryCardiology
2016English

Pirfenidone Should Be Prescribed for Patients With Idiopathic Pulmonary Fibrosis: Table 1

Thorax
PulmonaryRespiratory Medicine
2013English

Pirfenidone Treatment in Idiopathic Pulmonary Fibrosis: Nationwide Danish Results

European Clinical Respiratory Journal
2016English

Idiopathic Pulmonary Fibrosis: Lessons From Clinical Trials Over the Past 25 Years

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2017English

P196 Healthcare Utilisation by Patients With Idiopathic Pulmonary Fibrosis; Observations From the UK Pirfenidone Named Patient Programme

Thorax
PulmonaryRespiratory Medicine
2013English

Cardiovascular Risk in Idiopathic Pulmonary Fibrosis

International Journal of Pulmonary & Respiratory Sciences
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy